Glyphosate MDL Plaintiffs Present Exhibit About Monsanto's Lack Of Testing

SAN FRANCISCO - The plaintiffs in the multidistrict litigation for the herbicide Roundup on Jan. 25 filed exhibits in California federal court that are documents from a separate glyphosate case in which Monsanto Co. admits that it has not conducted a study specifically designed to examine if an association exists between glyphosate exposure and non-Hodgkin lymphoma (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news

Related Links:

CONCLUSIONS: Postmenopausal women with high/increasing ET are at increased risk of breast, ovarian and lung cancer. It is important that clinicians are aware of these risks as TVS is a common investigation. This article is protected by copyright. All rights reserved. PMID: 31614036 [PubMed - as supplied by publisher]
Source: The Ultrasound Review of Obstetrics and Gynecology - Category: Radiology Authors: Tags: Ultrasound Obstet Gynecol Source Type: research
Non-Hodgkin lymphoma (NHL) is typically sensitive to conventional doses of chemotherapy but many patients do not respond to front-line treatment or subsequently relapse after achieving remission. For medically-fit patients with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), subsequent treatment with high dose chemotherapy and autologous hematopoietic stem cell transplantation (ASCT) is often indicated [1 –4]. ASCT is also performed as consolidation treatment for patients with mantle cell lymphoma (MCL) and peripheral T-cell lymphoma (PTCL) and is associated with favorable progr...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Patients with a rare form of non-Hodgkin lymphoma who are followed with observation are labeled'asymptomatic,'but they are rarely symptom free.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
CONCLUSIONS: Determining the BDNF protein levels before initiating chemotherapy might be a useful tool for CIPN risk assessment and preemptive dose modification. The present data should be validated in larger studies that include other neurotoxic agents. PMID: 31591840 [PubMed]
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
AbstractPurposeInvasive pulmonary aspergillosis (IPA) is a dreadful event in patients with hematological malignancies (HM). Recent advances have standardized diagnostic, prophylactic and curative therapeutic strategies. We sought to assess whether these advances actually translate into improved survival in critically ill patients with acute respiratory failure and IPA.MethodsThis was a retrospective, multicenter study. Adult patients with HM, IPA, admitted to the ICU for acute respiratory failure over a 20-year period (January 1998 –December 2017) were included. A cox regression model was used to identify variables i...
Source: Intensive Care Medicine - Category: Intensive Care Source Type: research
We report a patient with HL and RDD involving the same lymph node concurrently. Both the areas were confirmed by histomorphology and immunohistochemistry (IHC). The detection of RDD in lymphoma cases is incidental and seems to have no clinical significance. Thus, finding of focal RDD does not affect therapeutic decisions of these patients. However, admixture of lymphoma cell population (both HL and NHL) along with histiocytic proliferation can be a diagnostic challenge at times, especially in inexperienced hands and a resource-limited setup where IHC is not available.
Source: Current Medicine Research and Practice - Category: General Medicine Source Type: research
Authors: Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ Abstract BACKGROUND: Provider experience, or clinical volume, is associated with improved outcomes in many complex healthcare settings. Despite increased complexity of anticancer therapies, studies evaluating physician-level experience and cancer treatment outcomes are lacking. METHODS: A population-based study was conducted of older adults (aged ≥66 years) diagnosed with B-cell non-Hodgkin's lymphoma in 2004 through 2011 using SEER-Medicare data. Analysis focused on outcomes in patients receiving rituximab, the ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
CD19-targeted chimeric antigen receptor modified T-cell immunotherapy (CD19 CAR-T cells) has shown excellent anti-tumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [1] and non-Hodgkin lymphoma (NHL) [2,3], which led to the approval of tisagenlecleucel (Kymriah ࣨ) and axicabtagene ciloleucel (Yescartaࣨ) by regulatory agencies in the United States, Europe, Canada, Japan and Australia. This approvalhas transformed the care of patients with relapsed/refractory ALL and aggressive B cell NHL [4-6].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Conference abstracts
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Contributors : Alexey V Danilov ; Nur BrussSeries Type : Expression profiling by arrayOrganism : Homo sapiensNovel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. We and others have shown that pevonedistat (TAK-924), a small molecule inhibitor of NAE, abrogates NF- κB signaling in malignant B cells. However, NF-κB pathway activity is indispensable in immun...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
More News: Legislation | Lymphoma | Medical Law | Non-Hodgkin's Lymphoma | Study | Toxicology